Imatinib for COVID-19: A case report.

Autor: Morales-Ortega A; Hospital Universitario de Fuenlabrada, Madrid. Spain. Electronic address: alejandro.morales@salud.madrid.org., Bernal-Bello D; Hospital Universitario de Fuenlabrada, Madrid. Spain., Llarena-Barroso C; Hospital Universitario de Fuenlabrada, Madrid. Spain., Frutos-Pérez B; Hospital Universitario de Fuenlabrada, Madrid. Spain., Duarte-Millán MÁ; Hospital Universitario de Fuenlabrada, Madrid. Spain., García de Viedma-García V; Hospital Universitario de Fuenlabrada, Madrid. Spain., Farfán-Sedano AI; Hospital Universitario de Fuenlabrada, Madrid. Spain., Canalejo-Castrillero E; Hospital Universitario de Fuenlabrada, Madrid. Spain., Ruiz-Giardín JM; Hospital Universitario de Fuenlabrada, Madrid. Spain., Ruiz-Ruiz J; Hospital Universitario de Fuenlabrada, Madrid. Spain., San Martín-López JV; Hospital Universitario de Fuenlabrada, Madrid. Spain.
Jazyk: angličtina
Zdroj: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2020 Sep; Vol. 218, pp. 108518. Date of Electronic Publication: 2020 Jun 27.
DOI: 10.1016/j.clim.2020.108518
Abstrakt: Competing Interests: Declaration of Competing Interest David Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. The rest of the authors are sub-investigators in this project. All authors declare no other competing interests.
Databáze: MEDLINE
Externí odkaz: